Empiric Anti-pseudomonal Activity in DFI
3 patients present with diabetic foot infections:
1. 
with osteomyelitis & recent culture growing MSSA
2. 
with blisters from new shoes
3. 
with recent culture growing P. aeruginosa
Who should receive EMPIRIC anti-pseudomonal coverage? 
How did others respond?
Reveal the answer
Best Answer
Patient 3 🧔🏻♂️ given recent growth of P. aeruginosa
Explanation: The 2023 IWGDF/IDSA Guidelines recommend AGAINST empiric Pseudomonal coverage in most patients 🚫
Studies tell us that Pseudomonas spp grows in <10% of all positive cultures in DFIs
Reasons for empiric Pseudomonal coverage include:
-residence in North Africa/Asia 🌍
-Pseudomonas spp isolated in culture in the last few weeks 🧫
Pause ⏸️ before adding empiric Pseudomonas coverage in diabetic foot infections 🦶